
Upperton Completes Build of New £7m Sterile Manufacturing Facility
Upperton completes build of new £7m Nottingham sterile manufacturing facility for parenteral, nasal and pulmonary delivery.
A purpose-built 7,000 sq ft facility, designed specifically in line with the revised EU GMP Annex-1 regulations, enables the development, manufacture, testing and fill/finish of sterile drug products for biologics and small molecules.
Alongside existing full-service formulation development and quality control laboratories, our team can support your drug development with expertise and speed. (Our facility is due to be operational in Q1 2026.)
Our contract manufacturing capabilities and successful regulatory history support you in maximising the success of your drug product.
Our sterile processing capabilities include:
– Sterile drug products – aseptically prepared.
– Liquid formulations and powders for parenteral, nasal and pulmonary delivery.
– Wide range of molecules from small molecules to biologics (including proteins, peptides and mAbs).
– Aseptically prepared lyophilized and spray-dried powders.
Our Leadership Team excels in steering products from pre-clinical to market. This extensive expertise forms the cornerstone of our service to you, ensuring hands-on involvement at every stage and every level of our business.
Alongside our upcoming aseptic capabilities, our formulation development across a broad range of dosage forms, clinical trial supply, and niche-scale commercial manufacturing for non-sterile dosage forms provides accessible scale-up and unparalleled project delivery.
Our team supports you in every aspect of analytical and microbial testing including the QP release of your final product.
We work to ensure the early identification of lead prototype formulations suitable for clinical testing followed by the development of your product through the product cycle.
Through ASAPprime® our teams generate robust, accelerated stability data, from API drug substance stability to formulation development prototypes and final dosage forms.
Our Grade C processing room features an Envair CIVAS Positive Pressure Solid Wall Processing Isolator, alongside…
360° image – drag to move around
Sterile fill-finish is the final step in the drug manufacturing process for injectable medications and other parenteral products. It involves filling the drug product into its final containers (such as vials, syringes, or cartridges) under strictly controlled aseptic conditions to ensure sterility.
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
Upperton completes build of new £7m Nottingham sterile manufacturing facility for parenteral, nasal and pulmonary delivery.
Upperton Pharma Solutions has announced a £5million investment to expand operations into small-scale sterile fill-finish.
Driven by experts, led by science
Integrated CDMO services
By Development Stage
Development Platforms
Route of delivery
About Us
Our Approach
Events
Resources
Policies
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA, UK. Phone: +44 (0) 115 855 7050 Email: contact@upperton.com
Copyright © 2025 Upperton Limited. Registration number: 03833301. Registered office address: Albert Einstein Centre, Nottingham Science Park, Nottingham, NG7 2TN. Registered in England. All rights reserved.
Speak with our team of experts and set up a discovery call to discuss your project in more detail.
Speak to one of our experts
Ready to discuss a project?